Early drug test focuses on safety for people with liver disease
NCT ID NCT06736223
Summary
This early-stage study aimed to understand how a liver condition changes the way the body processes a single dose of an experimental drug called ITF2357. It involved 24 people: 16 with mild or moderate liver impairment and 8 with normal liver function. The main goal was to measure drug levels in the blood and check for safety, not to treat the liver disease itself.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biotrial
Rennes, 35042, France
-
MC COMAC Medical Ltd
Sofia, 1606, Bulgaria
-
MC COMAC Medical Ltd
Sofia, 1612, Bulgaria
Conditions
Explore the condition pages connected to this study.